development pipeline

Our lead product candidate, brincidofovir, has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including the herpesviruses and adenoviruses. Brincidofovir has not been associated with kidney or bone marrow toxicity in over 1,000 patients treated to date. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.

We are working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure to treat potential smallpox outbreaks in the event of bioterror attacks or accidental release.